No Data
No Data
Healios to Consult FDA on Global Phase 3 Study for MultiStem in ARDS
Healios KK Advances Global Phase 3 Study for ARDS
Stocks that moved the previous day part 1 including Kakaku.com, Japan Steel Works, Keyence, etc.
Stock name <Code> 6-day closing price ⇒ Compared to the previous day, Kakaku.com <2371> increased by 400 and operating profit in the first quarter of 2024 increased by 34.9%. Nippon Steel Mining <1515> increased by 550 and operating profit in the first quarter increased by 65.9%. Nissui <1332> had a flat operating profit in the first quarter at +57.7 and temporarily struggled to grow in the afternoon. Joshi Denki <8173> decreased by 39 and operating profit in the first quarter decreased by 16.7% amidst a significant overall increase. Helios <4593> HLCR01 increased by 26.
Active and newly established stocks in the afternoon session.
*Kakaku.com <2371> increased its operating profit by 34.9% in the first quarter of 2024, with a gain of +400. *Nippon Steel and Mining <1515> increased its operating profit by 65.9% in the first quarter of 4290. *Nissui <1332> remained stagnant in operating profit in the first quarter, with an increase of +57.7, but struggled in the afternoon in a sharp rise. *J.A. Shirai Electric <8173> decreased its operating profit by 16.7% in the first quarter, with 2588 and sluggish performance amid a large overall increase. *Helios <4593> had subjects in clinical trials using HLCR011 and a 26-point increase.
Emerging Market Stock Digest: RoboPay rebounds sharply, Yutori hits limit up.
<4374> Robo-pay 2215 +422 sharply bounced back, temporarily hitting the limit up. The introduction of Weed's "SubscPay Professional" and its introduction case have been well received. "SubscPay Professional" is a customer management and automatic billing cloud service specialized in the subscription business. It has a wealth of features such as automatically collecting and analyzing customer lifecycles, such as contract details, purchasing trends, and usage status, in real time.
Healios KK, Sumitomo Pharma Initiate Clinical Trial for IPS-Derived RPE Cells; Healios Shares Up 15%
No Data